In a patient with elevated prolactin who is being evaluated by an endocrinologist and diagnosed with a prolactin‑secreting pituitary tumor (prolactinoma), how should the tumor be removed?

Prolactinomas Are NOT Routinely Removed Surgically—Medical Therapy Is First-Line

Prolactin-secreting tumors should NOT be surgically removed as initial treatment; dopamine agonist therapy (cabergoline or bromocriptine) is the primary treatment for virtually all prolactinomas. Surgery is reserved only for specific situations where medical therapy fails or cannot be used 1.

Medical Therapy Is the Standard of Care

The Endocrine Society guidelines are unequivocal: dopamine agonists are first-line treatment for prolactinomas, not surgery. This is because:

• Cabergoline achieves tumor shrinkage in >90% of patients and normalizes prolactin in approximately 90% of cases 1
• Bromocriptine reduces tumor size by ~50% in two-thirds of patients 1
• Medical therapy avoids surgical risks while effectively controlling both hormone levels and tumor mass

When Surgery IS Indicated (Specific Scenarios Only)

Transsphenoidal surgery should be offered only to symptomatic patients who meet these criteria 1:

Absolute Surgical Indications:

• Dopamine agonist resistance: Failure to normalize prolactin or achieve significant tumor shrinkage despite high-dose cabergoline
• Dopamine agonist intolerance: Severe side effects preventing continued medical therapy (even after trying intravaginal bromocriptine as alternative)
• Pituitary apoplexy: Acute hemorrhage into the tumor causing neurological emergency 2
• CSF leak: Cerebrospinal fluid fistula occurring after dopamine agonist-induced tumor shrinkage 2, 3
• Progressive visual deficits: Despite medical therapy 3

Important Caveats About Surgery:

Surgery has significant limitations 1:

• 7-50% recurrence rate for surgically resected prolactinomas
• Surgical complications include hypopituitarism, diabetes insipidus, CSF leak, and infection (though less common with experienced pituitary surgeons)
• Cure rates decline with tumor size: 64% for microadenomas, only 6.7% for macroadenomas, 0% for giant adenomas 4

The Treatment Algorithm

Step 1: Start Medical Therapy

• Initiate cabergoline as first-line (preferred) or bromocriptine
• Increase dose stepwise if inadequate response 1

Step 2: If Bromocriptine Fails

• Switch to cabergoline (80% of bromocriptine-resistant patients respond) 1

Step 3: If High-Dose Cabergoline Fails

• Increase cabergoline dose further before considering surgery 1
• For very high doses, monitor with echocardiography for valvular abnormalities 1

Step 4: Surgery Only After Medical Failure

• Offer transsphenoidal surgery only when medical therapy is truly inadequate or not tolerated 1

Step 5: If Surgery Fails

• Consider radiation therapy for aggressive or malignant prolactinomas 1
• For malignant prolactinomas with metastases, consider temozolomide chemotherapy 1

Critical Clinical Pitfall

The most common error is referring patients for surgery too early. The guidelines explicitly state: "For symptomatic patients who do not achieve normal prolactin levels or show significant reduction in tumor size on standard doses of a dopamine agonist, we recommend that the dose be increased rather than referring the patient for surgery" 1. Surgery should be considered only after maximizing medical therapy, not as a convenient alternative to dose escalation.

Special Consideration: Pregnancy

During pregnancy, if symptomatic tumor growth occurs, reinstitute bromocriptine therapy first—surgery is reserved only if medical therapy fails to reduce symptoms 1. If the fetus is near term, induce delivery before considering neurosurgical intervention 1.